Early vs. delayed screening for prostate cancer

Not Applicable

• Conditions: Prostate cancer; Cancer

• Registration Number: ISRCTN37591328
• Lead Sponsor: German Cancer Aid

Brief Summary

2023 Interim results article in https://doi.org/10.1016/j.eururo.2023.09.027 (added 23/10/2023)

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-01-15
• Last Update Posted: 6 November 2023
• Study Completion: 2034-04-30

Recruitment & Eligibility

• Status: Ongoing
• Sex: Male
• Target Recruitment: 46000

Inclusion Criteria

1. Males at age 45 at the time of consent
2. Willing and able to provide written informed consent
3. Written data protection consent has been obtained
4. Able to adhere to the study visit schedule and requirements of the protocol

Exclusion Criteria

Previous history of prostate cancer

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of metastatic prostate cancer up to the age of 60 as judged by imaging and confirmatory biopsy of metastases.

Secondary Outcome Measures

Name	Time	Method
<br> Measured by patient records:<br> 1. Incidence of late metastasis (M+ = radiographically and histologically proven bone metastases and/or radiographically and histologically proven nonregional lymph node or visceral metastases) after curative treatment (radical prostatectomy, radiotherapy) of detected prostate cancers up to the age of 60<br> 2. Incidence of biochemical recurrences after curative treatment (radical prostatectomy, radiotherapy) of detected prostate cancers up to the age of 60<br> 3. Locally advanced prostate cancers detected up to the age of 60<br> 4. Incidence of high-grade prostate cancers detected up to the age of 60<br> 5. The prostate cancer mortality rate up to the age of 60<br> 6. Overall survival up to the age of 60<br>